A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

Inclusion Criteria

• Histologically confirmed metastatic or locally advanced unresectable solid tumor. Must have received prior standard therapy.
• Measurable disease per RECIST 1.1
• Eastern Cooperative Oncology Group performance status of 0 or 1
• Adequate baseline laboratory values
• Patients of childbearing potential or those with partners of childbearing potential must agree to use a highly effective method of birth control from signing the ICF, and for a period of 30 days after the last dose of CX-904.
• Additional inclusion criteria may apply

Exclusion Criteria

• History of malignancy that was active within the previous 2 years. Exceptions include localized cancers that are not related to the current cancer being treated, that are considered to have been cured, and in the opinion of the Investigator, present a low risk of recurrence
• Screening electrocardiogram demonstrating a mean QTcF value > 480 msec; a screening echocardiogram with left ventricular ejection fraction (LVEF) < 50%
• Serious concurrent illness
• History of or current active autoimmune diseases
• History of myocarditis regardless of the cause
• Pregnant or breast feeding
• Additional exclusion criteria may apply